albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-07-27 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Dual incretin receptor agonist |
| Amino acid count | 39 residues | Includes non-natural residues |
| Approximate mass | 4.8 kDa | Reported values vary slightly by source |
| Fatty acid component | C20 diacid | Supports albumin binding |
| First US approval | 2022 | Glycemic indication, weight management followed |
As a peptide, tirzepatide is handled as a lyophilised solid in research settings and as a preserved solution in finished products. Aqueous solubility is pH dependent and reaches a minimum near the isoelectric point, which lies close to pH 5.4. Stock solutions are typically prepared in neutral or slightly basic buffer to limit precipitation. The solid is hygroscopic and should be equilibrated to room temperature before opening so that condensation does not form on the powder surface.
Recommended storage for reference material is a freezer at approximately -20 degrees Celsius, protected from light and moisture. Commercial injectable presentations are stored refrigerated between 2 and 8 degrees Celsius and must not be frozen. Product labelling generally permits a limited period at controlled room temperature once dispensed, with the exact window depending on the presentation. Repeated temperature cycling is avoided because it can promote aggregation or deamidation of the peptide chain.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, with mass confirmation by electrospray ionisation mass spectrometry. Peptide mapping after enzymatic digestion verifies the primary sequence. Size-exclusion chromatography quantifies aggregates, while circular dichroism provides a secondary-structure fingerprint. Bioanalytical quantification in plasma uses immunoassay or LC-MS/MS. Reported purity for research-grade lots is commonly 95 percent or higher, and residual water content is checked by Karl Fischer titration.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
According to a report submitted to the Japanese Pharmaceuticals and Medical Devices Agency regarding Glanatec, ripasudil hydrochloride hydrate showed no binding affinity for receptors of the adrenergic, angiotensin II, endothelin, glutamate, histamine, muscarinic, or prostanoid variety. This lack of affinity also applies to Ca2+ and K+ channels, carbonic anhydrase, and HMG-CoA reductase. Toxicity information is compiled in the following tables.
=== Cholesterol control === There is inconsistent evidence regarding the effect of LDL-cholesterol levels on stroke risk after TIA. Elevated cholesterol may increase ischemic stroke risk while decreasing the risk of hemorrhagic stroke. While its role in stroke prevention is unclear, statin therapy has been shown to reduce all-cause mortality and may be recommended after TIA.
The chemical nature of the stationary phase. The stationary phase can be coated with some ligands at different bonding densities (how many ligands are bonded per surface area). The composition of the mobile phase. The mobile phase may be made of one solvent, or a mixture of several solvents. The solvents can be mixed at different ratios. Different mobile phases have different properties, such as polarity. When a mobile phase consists of mostly one solvent, with some other solvents added in small amounts, those other solvents are called "mobile phase modifiers". The pH of the mobile phase, which affect the ionization state of the solutes and their polarity. This can be changed with additives such as buffers. Usually, the stationary phase is made of a layer of hydrophobic substrate bonded to the surface of porous silica gel particles. The particles come in various shapes (spheric, irregular), at different diameters (sub-2, 3, 5, 7, 10 μm), with varying pore diameters (60, 100, 150, 300 Å). The particle diameters are often given as mesh numbers. For example, 2500-mesh corresponds to a particle diameter of 5 μm. The hydrophobic substrates are generally alkyl chains, such as C3, C4, C8, C18, or more. The longer the chain, the longer the sample components will be retained. It would make the resolution power higher, but also make the chromatography take longer to run. Most current methods of separation of biomedical materials use C18 columns, sometimes called by trade names, such as ODS (octadecylsilane) or RP-18 (reverse phase 18).
== Symmetric hydrogen bond == A symmetric hydrogen bond is a special type of hydrogen bond in which the proton is spaced exactly halfway between two identical atoms. The strength of the bond to each of those atoms is equal. It is an example of a three-center four-electron bond. This type of bond is much stronger than a "normal" hydrogen bond. The effective bond order is 0.5, so its strength is comparable to a covalent bond. It is seen in ice at high pressure, and also in the solid phase of many anhydrous acids such as hydrofluoric acid and formic acid at high pressure. It is also seen in the bifluoride ion [F···H···F]−. Due to severe steric constraint, the protonated form of Proton Sponge (1,8-bis(dimethylamino)naphthalene) and its derivatives also have symmetric hydrogen bonds ([N···H···N]+), although in the case of protonated Proton Sponge, the assembly is bent.
Sources: en.wikipedia.org
== Cultivation == Cut flower cultivation is intensive, usually on the basis of greenhouse monocultures, and requires large amounts of highly toxic pesticides, residues of which can often still be found in flower shops on imported flowers. As with the production of fruit and vegetables, the industry depends on significant amounts of water, which may be collected and stored by the farm owners. The Patel Dam failure in May 2018, associated with a large Kenyan rose farm, killed dozens of people. These facts have spurred the development of movements like "Slow Flowers", which propagates sustainable floriculture in the consumer country (US, Canada) itself.
=== 2000–present === In September 2002, Lilly partnered with Amylin Pharmaceuticals to develop and commercialize Amylin's new drug based on exendin-4, a novel substance isolated from the venom of the Gila monster. Exenatide, the first of the GLP-1 receptor agonists, was approved by the US Food and Drug Administration in April 2005. In 2003, Lilly introduced Cialis (tadalafil), a competitor to Viagra for erectile dysfunction developed in a partnership with Icos. Cialis maintains an active period of 36 hours, causing it sometimes to be dubbed the "weekend pill". It was advertised during the 2004 Super Bowl XXXVIII and 2005 Super Bowl XXXIX halftime shows. In 2004, Lilly introduced duloxetine (Cymbalta), a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder. It ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis. In January 2007, Lilly acquired Icos for $2.1 billion, after raising its offer and facing opposition from Institutional Shareholder Services. Lilly subsequently closed Icos' manufacturing operations, terminated nearly 500 Icos employees, leaving 127 employees working at the biologics facility. In December 2007, CMC Biopharmaceuticals A/S (CMC), a Copenhagen-based provider of contract biomanufacturing services, bought the Bothell, Washington-based biologics facility from Lilly and retained the existing 127 employees.
=== Discontinued === AS-601811 – oral – male pattern baldness – 5α-reductase inhibitor ATI-501 (A-201; ATI-50001) – oral – alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor Brepocitinib (PF-06700841) – oral – alopecia, alopecia areata – Janus kinase 1 inhibitor, TYK2 kinase inhibitor Cioteronel (CPC-10997; Cyoctol, X-Andron) – topical – alopecia – androgen receptor antagonist Diazoxide – topical – alopecia – potassium channel opener Denileukin diftitox (Lymphirtm, Ontak, Remitoro; LY-335348; DAB389 interleukin-2) – unknown – alopecia – protein synthesis inhibitor Epristeride (Aipuliete; ONO-9302, SKF-105657) – oral – alopecia – 5α-reductase inhibitor Etrasimod (Verespiti, Velspity; APD-334, PF-07915503) – oral – alopecia areata – sphingosine 1 phosphate receptor modulator Farudodstat (ASLAN-003, LAS-186323) – oral – alopecia areata – dihydroorotate dehydrogenase inhibitor HST-001 (HSC-660) – intradermal – alopecia – intercellular signalling peptide and protein replacement Ifidancitinib (A-301, ATI-50002, ATI-502) – topical – alopecia, alopecia areata – Janus kinase 1 inhibitor, Janus kinase 3 inhibitor MK-434 (MK-0434) – oral – alopecia – 5α-reductase inhibitor Naminidil (BMS-234303) – topical – alopecia – potassium channel opener NEOSH–101 – topical – alopecia – undefined mechanism of action P-1075 – unknown – alopecia – potassium channel opener Piliel – topical – alopecia – undefined mechanism of action Research programme: androgen receptor antagonists - Endoceutics (EM-4350, EM-6537) – unknown – male pattern baldness – androgen receptor antagonists Research programme: oligonucleotide therapeutics for alopecia - OliPass – unknown – alopecia – androgen receptor antagonists RU-58841 (PSK-3841, HMR-3841) – topical – alopecia – androgen receptor antagonist Secukinumab (Cosentyx) – injection – alopecia areata – IL17A protein inhibitor Setipiprant (ACT-129968, KYTH-105) – oral – alopecia – prostaglandin D2 receptor antagonist Timbetasin (thymosin β4) – unknown – alopecia – various mechanisms of action Tralokinumab (Adbry, Adtralza; CAT-354, LP-0162) – subcutaneous injection – alopecia areata – interleukin-13 inhibitor TU-2100 – topical – hair disorders – undefined mechanism of action Viprostol (CL-115347) – topical – alopecia – synthetic prostaglandin E2 analogue
Sources: en.wikipedia.org
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.
United States approval for type 2 diabetes was granted in 2022, and a chronic weight management indication was added later. Approval timelines differ across other jurisdictions. Earlier human data came from phase 1 and phase 2 trials published before those decisions.
Native hormones are short-lived peptides that enzymes degrade within minutes. Tirzepatide carries non-natural residues and a fatty acid chain that resist this breakdown and extend circulation time. The result is a longer interval between administrations than the natural hormones could support.
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.